Introduction
The recent completion of the human genome project coupled with the amount of information that is beginning to be generated by high-throughput technologies has revolutionalized the concept of personalized cancer risk assessment, genetic counselling and management. As a result, clinical cancer genetics is increasingly becoming an integral part of modern practice in which genetic markers are routinely used for early cancer diagnosis, clinical surveillance, treatment and prevention decisions. Despite these advancements, in practice, it is still a challenge to discriminate heritable cancers from sporadic ones, due to a lack of differentiable clinical features.
For the advances in both genetic-and molecularbased diagnostic testing to have genuine effect, there needs to be a robust integration and synthesis of all the data generated from multidisciplinary sources. This means that many layers of complexity will be encountered, for example, a phenotype can be derived from the clinical, molecular and cellular levels. The combined global phenotype, involving data generated from clinical, molecular and cellular analysis will require the maturation of phenomics. Phenomics is the systematic and meticulous collection, objective documentation and cataloguing of phenotypic data at many levels (Eng, 2003; Zbuk and Eng, 2007) . In addition, the advancements in genomics, interactomics, phylomics and other '-omics' are also sources of the overabundance of information requiring advanced methodologies of integrating, synthesizing and tailoring data towards improving the specificity of personalized medicine for hereditary cancers. The meticulous phenomic analysis of the tumour suppressor gene PTEN (Phosphatase and TENsin homologue deleted on chromosome TEN) has led, not only to molecular-based personalized genetic management, but also to clues about the fundamental function of the gene and its pathway.
This article reviews the profiling of various genetic alterations of PTEN and its interacting counterparts from a multidisciplinary perspective in an attempt to understand the effects of genetic changes in PTEN and the resultant diverse PTEN hamartoma tumour syndrome (PHTS) phenotype. This is an essential step to the practice of personalized genetic health care. Although this review will focus on hereditary cancer predisposition, some of the '-omics' tools discussed undoubtedly will be applicable to sporadic cancers and their somatic profiles.
PTEN hamartoma tumour syndrome
Germline mutations in PTEN, on 10q23.3, have been found in 85% of Cowden syndrome (CS) cases and subsets of the unrelated syndromes including 65% of Bannayan-Riley-Ruvalcaba syndrome (BRRS) cases (Marsh et al., 1999a; Eng, 2000) , 20% of Proteus syndrome cases and Proteus-like syndrome (Marsh et al., 1997a (Marsh et al., , 1998b (Marsh et al., , 1999a Zhou et al., 2000 Zhou et al., , 2001 Zhou et al., , 2003b Smith et al., 2002) . These phenotypically diverse disorders share several overlapping clinical features and a common genetic aetiology, which has led to their genebased classification of PHTS (Marsh et al., 1998b (Marsh et al., , 1999a . The broad, apparently difficult to predict, clinical manifestations of PHTS mandate thorough and meticulous phenomic analysis to ensure recognition and then proper diagnosis of patients who are at risk of developing neoplasia.
Although heritable PTEN mutations have been identified in a significant number of patients diagnosed with PHTS, for many patients with these related syndromes, the aetiology of the disease remains unknown (that is, 15% CS and 35% BRRS without a recognized genetic cause). In addition, due to the variable clinical presentation of the syndromes, patients with a less severe phenotype, for example, those who do not meet full clinical criteria (termed CS-like; CSL) may be difficult for a clinician, even well-trained clinical cancer geneticists and genetic counsellors, to recognize, let alone offer PTEN mutation analysis. The mutation frequency of PTEN in CS-like individuals is about 5-10% if the mutations in the promoter or deletions in PTEN are omitted (Marsh et al., 1998a) . The lack of detectable germline alterations in PTEN in subsets of CS, CS-like and BRRS patients has stimulated the need to investigate alternate mechanisms of PTEN dysfunction, both genetic and biochemical.
There are several strategies that can be used to extract the plethora of genetic information from PTEN and its pathways for the purpose of understanding the PHTS phenotype. These strategies include analysing the frequency of germline mutations (that is, missense mutations, insertions and deletions, and promoter variants), determining their correlation with PHTS and documenting the mutation-specific clinical phenotype (reviewed by Zbuk and Eng, 2007) . Of particular interest are the germline variants of unknown significance, which, while contributing to the difficulty of interpreting true pathogenicity, may provide useful information to elucidate a broader understanding of the phenomics surrounding PTEN. Clinical management of such patients needs to be highly individualized and must take into consideration factors such as the patient's personal and family cancer history, the likelihood that the variants of unknown significance are significant, as well as functional studies. Importantly, it should be noted that the classification of a sequence variant as a variant of unknown significance often changes as additional genetic information is accrued. Previously reported variants of unknown significance can be reclassified as polymorphisms and occasionally as deleterious mutations, which may impact the continuing care of patients.
PTEN molecular structure
PTEN encodes two major functional domains, an N-terminal domain encompassing exons 1-6 and a C-terminal domain encompassing exons 6-9 (Lee et al., 1999) . As a dual-specificity tumour suppressor phosphatase, PTEN dephosphorylates both protein and lipid substrates (Myers et al., 1997; Maehama and Dixon, 1998) . Exon 5, at the N terminus, encodes the phosphatase domain, which contains the consensus catalytic core motif, CKAGKGR, defined by amino acids 124-130. Germline mutations cluster in this region and confirm its fundamental role in both biology and disease. At the C terminus are the lipid-binding C2 domain, two PEST (that is, motif rich in proline (P), glutamate (E), serine (S) and threonine (T), which enhance proteolytic sensitivity) domains and a PDZ (derived from its appearance in ZO-1 a zonula occludens protein, an important signalling protein) domain, regions thought to be important in maintaining PTEN stability and facilitating protein-protein interactions (Lee et al., 1993 (Lee et al., , 1999 Georgescu et al., 1999) (Figure 1) . PTEN structure and function are reviewed in detail elsewhere in this issue.
Germline mutations in the PTEN coding region in human disorders
The main process of germline PTEN inactivation in CS involves intragenic changes including point mutations within PTEN's coding sequence. To date, 80% of individuals with CS have been found to harbour germline mutations within the first eight exons of the gene (Eng, 2000; Zbuk and Eng, 2007) (Figure 1 ). Approximately, 67% of the germline mutations identified in CS localize to exons 5, 7 and 8, with more than 40% of these located in exon 5, which also encodes the phosphatase core motif (Marsh et al., 1998b) . A strong correlation between missense mutations within the phosphatase core motif with disease severity in CS patients provides a strong association between the mutation spectrum of PTEN and the resultant clinical phenotypes observed in CS patients (Marsh et al., 1998b) (Figure 1 ). Missense mutations within and 5 0 of the phosphatase core motif appear to be associated with at least five more organs, a surrogate phenotype for severity of disease (Marsh et al., 1998b) . The differences in mutation frequency between the studies by Marsh et al. (1998b) and Nelen et al. (1999) reflected an increased stringency of ascertainment by the International Cowden Consortium criteria and a small sample size in the latter study (reviewed by Waite and Eng, 2002) . The two studies relay the importance of accuracy and consistency in CS diagnosis and the sample size used in analyses to predict the risk of the disease.
Genetic alterations in the PTEN promoter
Initial linkage analysis on a limited but informative set of CS families suggested linkage to 10q23 but did not show genetic heterogeneity among families that originated from four different countries (Nelen et al., 1996) . Therefore, a search for germline mutations and deletions within at least the minimal PTEN promoter region was warranted for the classic CS and BRRS probands who were without intragenic PTEN mutations (Zhou et al., 2003a) . The study by Zhou et al. (2003a) showed that 3 out of 27 (10%) mutation-negative BRRS patients were positive for large germline deletions, one of which encompassed the entire PTEN, the second included the first exon and the third included PTEN's exons 1-5 (Figure 1 ). Promoter analysis revealed nine (10%) cases with deletions in mutation-negative CS patients. Further, protein analysis showed that both deletion and promoter-positive mutations resulted in aberrant PTEN expression and elevated phospho-AKT observed in five of the promoter mutation-positive CS patients. The data suggested that CS and BRRS patients who are mutation-negative for intragenic PTEN mutations should be offered deletion analysis and promotermutation analysis as part of clinical routine.
Transcription factor profiling and functional analyses
It is known that PTEN has a significant role in regulating the cell cycle and in the malignant transformation associated with carcinogenesis (Myers et al., 1998; Stambolic et al., 1998; Maehama and Dixon, 1999; Weng et al., 2001b Weng et al., , 2002 Eng, 2003) . But relatively little is known about the mechanisms that govern transcriptional regulation of PTEN expression and its tentative effect in human heritable disorders such as CS and BRRS. In addition to pathogenic alterations within PTEN's exonic sequences, in vitro studies have identified functional consensus binding sites for transcriptional activators p53, early growth response-1, peroxisome proliferator-activated receptor-g, nuclear factor-kB, c-Jun and CBF-1 in the PTEN core promoter region (Patel et al., 2001; Zhou et al., 2003b; Vasudevan et al., 2004; Hettinger et al., 2007; Whelan et al., 2007; Teresi et al., 2008) . Some of these mutations, either in the promoter region or in the translation start sites, have been observed in a subset of CS patients lacking mutations in the coding regions (Stambolic et al., 2001a; Virolle et al., 2001; Zhou et al., 2003b; Tang and Eng, 2006b ).
The p53 tumour suppressor interacts with PTEN in a complex manner. First, it acts as a transcription factor, upregulating PTEN gene expression (Stambolic et al., 2001a) . Second, p53 physically interacts with the PTEN protein, resulting in stabilization of p53, but destabilization of PTEN, the latter partially due to caspase-related degradation (Tang and Eng, 2006a) . Thus, in addition to regulating PTEN gene expression, PTEN and p53 also physically interact, forming a complex that serves to autoregulate PTEN's own expression ( Figure 2a) .
After examining the downstream effect of five PTEN promoter variants in five patients diagnosed with breast, thyroid and/or endometrial cancer, Teresi et al. (2007b) demonstrated that three patients with variants À861G/T, À853C/G and À764G/A respectively, had an B50% decrease in PTEN protein expression. The À861G/T and À853C/G variants are both within the minimum PTEN promoter region, and the À764G/A variant is within the p53-binding domain (Sheng et al., 2002) . The variants did not alter PTEN mRNA levels, but instead resulted in different PTEN 5 0 -untranslated region transcript-folding patterns. This variant-associated altered RNA secondary structure could account for the unaltered transcript levels and decreased PTEN protein 
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Figure 2 (a) PTEN-AKT pathway and autoregulation of PTEN. The figure shows the PTEN phosphatase activity (that is, -P) from PI-3,4,5-(PO 4 ) 3 to PI-4,5-(PO 4 ) 2 and tentative effect on the influence of AKT pathway on downstream effectors BAD, mTOR, MDM2, LKB1, TSC1/2 and FOXO1 (reviewed in detail by others in this review issue). In addition, the complex between the p53 and PTEN is also shown. p53 upregulates PTEN gene expression and physically interacts with PTEN, forming a complex that serves to autoregulate PTEN's own expression (Stambolic et al., 2001a; Tang and Eng, 2006a) . (b) The BMP2, dephosphorylation-phosphorylation and ubiquitin-proteosome degradative pathways. BMP2 initiates at least two signalling pathways. One of the pathways involves the dephosphorylation-phosphorylation activity, in which the BMPR1A is phosphorylated and in turn initiates the SMAD4 pathway activity. The MAP kinase pathway, initiated by TGFb (not shown in this figure) also bifurcates from BMPR1A. SMAD4 stimulation signals other downstream effectors that may be associated with CS/BRRS. Mutations in BMPR1A or SMAD4 in CS/BRRS mutationnegative patients have been shown previously (Zhou et al., 2001 ). In addition, juvenile polyposis syndrome has also been associated with BMPR1A and SMAD4. The other pathway that BMP2 initiates is a non-phosphatase-dependent degradative pathway. BMP2 interacts with UbCH7 and UbC9 proteins and in the process, decreases the association of PTEN with the two proteins in the ubiquitinproteosome degradative pathway. This process increases PTEN levels, suggesting that BMP2 stimulation inhibits PTEN protein degradation. The increased PTEN levels most likely are reserved in the nucleus ready to use when needed. BRRS, Bannayan-RileyRuvalcaba syndrome; CS, Cowden syndrome; TGFb, transforming growth factor-b.
levels that were observed (Teresi et al., 2007b) . Therefore, the variants that caused large mRNA secondary structure alterations could inhibit protein translation leading to CS via a novel regulatory mechanism.
Distinct PTEN haplotypes associated with CS and CSL
The extent of linkage disequilibrium across the PTEN region was examined in 2006 (Haiman et al., 2006) . In addition, Pezzolesi et al. (2006) around the same time took advantage of PTEN's linkage disequilibrium pattern to construct and analyse its haplotypes. Haplotype patterns generated from the PTEN region helped infer the effect of rare mutations that might have been missed by standard mutation scanning or genotyping methodologies in classic CS patients. Several distinct haplotype blocks as well as 'rare' and extended haplotypes, spanning the PTEN locus in PHTS cases, were found to be significantly different from those of controls (Pezzolesi et al., 2006) (Figure 3) . Clearly, from this study, the range of allelic combinations that resulted from the constructed PTEN haplotypes can help explain the phenotypic complexity seen in CS and BRRS. The data also suggested that unique haplotypes, harbouring rare alleles, may be of lowpenetrance cis-modifying loci, which contribute to pathogenicity and underlie the disease aetiology. Because the so-called haplotype block 1 was in strong linkage disequilibrium with PTEN mutation-'negative' CS and CS-like individuals, Pezzolesi et al. (2007) decided to look for the most highly conserved regions encompassed within haplotype block 1, arguing for important function. Comparative genomic analyses revealed a highly conserved region 2 kb upstream of PTEN, well upstream of the 5 0 extent of the known full promoter region of the gene (Pezzolesi et al., 2007) . This led to the identification of germline deletions of the E-boxlike motif in this upstream region (that is, 800 bp upstream of the PTEN core promoter) in a subset of mutationnegative CS patients (Pezzolesi et al., 2007) . Indeed, the transcription factors USF-1 and USF-2 were shown to bind the E-box sequence (Pezzolesi et al., 2007) .
PTEN splice variants and possible role in CS phenotype
Although RNA splicing is essential in generating protein diversity, which is important in biological functions, alternative RNA processing has been witnessed in human cancer during transformation and/or acquisition of metastasis (Hsieh et al., 1999; Philips and Cooper, 2000; Poola and Speirs, 2001; Bracco and Kearsey, 2003; Faustino and Cooper, 2003; Agrawal and Eng, 2006) . Therefore, the possible occurrence of different splice variants (SV) and the probable association with the risk of developing cancer have stimulated researchers to study the fundamental impact of various splicing alterations on the behaviour of the protean presentations of CS, CS-like and BRRS (Poola and Speirs, 2001; Bracco and Kearsey, 2003; Faustino and Cooper, 2003; Agrawal and Eng, 2006) . Although the true function of the SV appearing in both normal and cancerous tissues is still unclear, it is possible that information gathered from specific SV can distinctively help identify CS, CS-like and BRRS cases, especially in the mutation-'negative' setting (Wang and Chang, 1999; Sarquis et al., 2006) . Sarquis et al. (2006) compared the relative expression of full-length PTEN transcript and eight PTEN SVs in 85 patients with CS/BRRS (regardless of PTEN mutation status) compared with 27 controls. The comparison yielded a relative underexpression of SV3a and SV3b and an overexpression of SV5b among patients. Further, an SV expressional genotype-phenotype correlation showed SV expressional profiles that were distinct among CS, CS-like and BRRS cases. The reduced full-length PTEN transcript expression was associated with differential expression of PTEN SVs, regardless of PTEN mutation status, supporting the concept that modulation of PTEN inactivation may also occur at the transcription level thereby influencing the specific phenotypes seen in these syndromes.
The effects of expressed SVs on AKT phosphorylation and cyclin D1 promoter activity have been evaluated, at least in vitro. SV5b overexpression in CS and CS-like cases showed increased cyclin D1 promoter activity in vitro, antagonistic to the action of PTEN protein . SV5a, on the other hand, functioned in a manner similar to that of PTEN, slightly decreasing AKT phosphorylation and cyclin D1 promoter activity, which partially compensates for altered PTEN function . Hence, decoding additional SVs and characterization of the relative expression levels of these different PTEN SVs in a large series of germline PTEN mutationpositive and -negative patients with PHTS spanning various phenotypes are warranted. Other studies that have shown the degree of specific alternatively spliced mRNAs have provided useful biomarkers and a better understanding of BRCA1, MDM2 and WT1 gene functions (Bartel et al., 2004; Brinkman, 2004) .
Potential clinical pathology and genetic heterogeneity in PHTS
The original linkage study, which mapped the CS susceptibility locus to 10q22-q23, showed that CS had no genetic heterogeneity (Nelen et al., 1996) . Subsequently, when germline mutations in PTEN, on 10q23.3, were found, at least one other study believed that there may be minor genetic heterogeneity for CS (Tsou et al., 1997) . Because the original linkage study revealed no genetic heterogeneity, related genes in the 10q22-24 region were viewed as candidate genes in PTEN mutation-negative CS (Nelen et al., 1996) . MINPP1, encoding inositol polyphosphate 3-phosphatase, on 10q23.3, was particularly attractive because it had overlap activity with PTEN, and the gene was only 310 kb upstream of PTEN with its 3 0 region within the CS critical interval (Chi et al., 1999) . Unfortunately, no germline mutations in MINPP1 were found in PTEN mutation-'negative' CS/BRRS, although these analyses were performed at a time when the PTEN promoter was yet to be identified and germline deletion/rearrangements had not been assayed for (Dahia et al., 2000) . Although BMPR1A on 10q22 lay outside the 5 0 boundary of the CS critical interval (746.9 kb upstream of D10S579), several clues pointed to some relationship with PTEN and CS. It is one of the two known major susceptibility genes (SMAD4) for juvenile polyposis syndrome (JPS), an autosomal dominant condition characterized by hamartomatous gastrointestinal polyps that turn into malignant lesions (Howe et al., 1998 (Howe et al., , 2001 Eng, 2001) . Whereas hamartomatous polyps, and occasionally juvenile polyps, are features of CS, albeit not prominent, these represent a shared phenotype with JPS. In addition, intestinal hamartomatous polyposis in BRRS can be severe and symptomatic. Mutation analysis was therefore performed and BMPR1A germline mutations were found in a minor subset of CS families (Zhou et al., 2003b) . Subsequently, it was shown that BMP2, the major ligand for BMPR1A (Figure 2b ), stabilized PTEN protein by decreasing the interaction of PTEN with two ubiquitin-conjugating enzymes UbCH7 and UbC9, presumably decreasing PTEN's entry into the ubiquitin-proteosome degradative pathway (Figure 2b ) (Waite and Eng, 2003) . Shortly after PTEN was described as the CS and BRRS susceptibility genes Marsh et al., 1997a) , there was a puzzling report that two JPS individuals also had germline PTEN mutations (Eng and Peacocke, 1998) . On closely reviewing the latter, however, it would appear that one patient had features consistent with CS and the other was too young to determine clinical diagnosis (Eng and Peacocke, 1998) . Nonetheless, a report of a severe case of JPS with a large deletion including PTEN (Tsuchiya et al., 1998) as well as a report of a case of BRRS with large deletion encompassing PTEN (Arch et al., 1997) appeared contradictory because PTEN was excluded as a JPS locus (Marsh et al., 1997b) . Subsequently, it turns out in fact that germline deletions of 10q22-q24 encompassing both PTEN and BMPR1A were found in, and likely represent the genetic sine qua non of, a special clinical entity termed juvenile polyposis of infancy, usually an extremely severe polyposis, diagnosed before the age of 3 years, and resulting in early death (Delnatte et al., 2006) .
It became obvious that not only are the nonadenomatous polyposes extremely heterogeneous clinically and aetiologically, but also they were difficult to be differentiated using only clinical phenotype. Teleologically, some believe that this is due to the cross talk among the pathways involved (Figure 2b ). To systematically classify patients with five or more unexplained hamartomatous or hyperplastic/mixed polyposis (regardless of age or family history), extensive germline sequencing and deletion analyses of PTEN, BMPR1A, SMAD4, STK11 (the susceptibility gene for PeutzJeghers syndrome), MYH (MYH-associated polyposis) and BHD (Birt-Hogg-Dube´syndrome) were performed in a series 49 eligible patients (Sweet et al., 2005) . Two sets of results were seen. For the first group of clinically positive PJS or JPS patients, 5 of 17 (29%) were tested mutation-negative for all the known JPS and PJS genes in clinical diagnostics labs, of which one JPS patient showed a large 1.2-Mb deletion encompassing BMPR1A and PTEN. Another PJS patient showed a hemizygous deletion of the PTEN promoter region and exon 1. Among the second group of 23 patients with hyperplastic/mixed polyposis, two (9%) had germline PTEN mutations. Interestingly, patients who showed deletion in PTEN lacked the characteristic CS mucocutaneous pigmentation and had been diagnosed solely on polyp histology results. As part of this study, histopathology was read in a blinded fashion from the clinical and the genetic diagnoses by a single specialist gastrointestinal cancer pathologist. Importantly, he found multiple discrepancies between his readings and those that these patients' polyps received from their respective hospitals (ranging from community hospitals to tertiary referral centres). In fact, the gastrointestinal pathologist's reading concurred with the molecular classification. Therefore, phenotypic features that are shared by a number of hamartoma syndromes require a molecular analysis of a set of the known susceptibility genes for patients who have suggestive clinical and histopathologic features but who are negative for mutations in the most obvious genes. Although often difficult, all polyp histologies should be re-reviewed by a gastrointestinal pathologist.
PICT-1 (protein interacting with carboxyl terminus), a PTEN-interacting protein, has been shown to promote phosphorylation and stability of PTEN by binding to PTEN's C terminus (Okahara et al., 2004) . Okahara et al. (2004) showed that PICT-1 is involved in the molecular mechanism underlying the turnover of PTEN and explained the loss of PTEN function associated with C-terminal mutations, demonstrating an additional mechanism of PTEN dysfunction. In BRRS, the extent of genetic heterogeneity is unclear but it is likely that other mechanisms, such as modifiers of PTEN, for instance, other genes or environmental factors, may be influential of this syndrome (Hamilton et al., 2000; Haiman et al., 2006; Zhang et al., 2006) . Similarly, other possible potential networks of trans-interacting genes and/or their products, which are yet to be identified, are very likely to be influential in the PHTS phenotype as evidenced by their roles in the various PHTS syndrome pathways. The genes in these crosstalking pathways are potential candidate genes by the mere fact that they or their products participate in the various PHTS pathways and can influence the diverse phenotypes observed in PHTS patients.
PTEN phosphatase-dependent and phosphataseindependent roles
In clinical practice, especially in the tertiary referral setting, PHTS patients appear to present with diverse and often subtle phenotypes, suggesting a complex interplay between PTEN-related pathways and multiple levels of regulation.
The phosphoinositides (for example, phosphatidylinositol-3,4,5-triphosphate (PI-3,4,5-(PO 4 ) 3 )) have been shown to directly activate enzymes (for example, AKT/ PKB) or direct proteins to various subcellular locations through lipid binding (Vazquez et al., 2000) . Pathways involving the AKT, MAPK, mTOR and other molecules downstream of PTEN are important (Figure 2a ) and are extensively reviewed elsewhere in this issue. Most naturally occurring mutations in PTEN are both lipid-and protein-phosphatase inactive (Eng, 2003) also (reviewed by Waite and Eng, 2002) ; in addition to the lipid -and protein phosphatase-bifurcated activities, alterations in subcellular localization of PTEN provide another regulation mechanism (Weng et al., 2001a (Weng et al., , b, 2002 .
Previously, the assumptions were that all the functions of PTEN occurred through cytoplasmic PTEN. However, immunohistochemistry studies showed that PTEN localizes to the nucleus of normal cells and decreased nuclear PTEN in MCF-7 breast cancer cells. Ginn-Pease and Eng (2003) were the first to demonstrate that PTEN enters the nucleus and that nuclear PTEN varies throughout the cell cycle. Higher nuclear PTEN levels were associated with G0-G1 phase, and lower nuclear PTEN levels were associated with S phase, an indication that PTEN shuttling may be associated with the regulation of the cell cycle (Ginn-Pease and Eng, 2003) .
PTEN was shown to have a bipartite nuclear localization sequence-like sequences, which are required for major vault protein (MVP)-mediated nuclear import (Chung and Eng, 2005) . To further this finding, subcellular localization of PTEN was re-examined to determine if nuclear-localized PTEN can regulate unique cellular functions that have been previously attributed to cytoplasmic PTEN. Two different nuclear localization sequence mutant PTEN constructs that did not localize to the nucleus were compared with cells transfected with wild-type PTEN and empty vector control cells (Chung and Eng, 2005) . The result was that cytoplasmic PTEN downregulates phosphorylation of AKT, upregulates p27 kip1 and are most likely required for apoptosis. On the other hand, nuclear PTEN downregulates cyclin D1, prevents the phosphorylation of MAPK and was essential for cell cycle arrest. These observations show that nucleocytoplasmic partitioning differentially regulates the cell cycle and apoptosis and, in this manner, provide further evidence that nuclear import of PTEN should play a role in carcinogenesis. Further, from the same four cell lines, Chung et al. (2006) demonstrated that nuclear PTEN downregulates cyclin D1 transcription and that the event was mediated by the downregulation of MAPK. These results provide additional evidence that nuclear PTEN plays a role through cell cycle suppression functions in regulating carcinogenesis. Another study went on further to investigate the exact mechanism of MVP-mediated nucleocytoplasmic shuttling. The study showed that small interfering RNA-mediated MVP silencing decreased the nuclear localization of PTEN and increased the phosphorylation of nuclear p44/42. An in situ study further showed that PTEN-MVP interaction is Ca 2 þ -dependent, where an increased Ca 2 þ decreases the nuclear localization of PTEN. Further, Ca 2 þ ionophore A23187 increases nuclear localization of PTEN and decreases phosphorylation of nuclear p44/42. These findings suggest that Ca 2 þ regulates the nuclear entry of PTEN through a tyrosil phosphorylation-independent conformational change in MVP. Combined, data generated by Minaguchi et al. (2006) present evidence of a novel cross talk between the Ca 2 þ signallingmediated regulation of the cell cycle and the MVPmediated nuclear PTEN localization and function.
Recently, nuclear PTEN was shown to maintain chromosome stability by physically associating with centromere-specific binding protein C (CENP-C) (Shen et al., 2007) . PTEN was found to be necessary and sufficient for the induction of RAD51, which is important for the chromosome double-stranded break repair. PTEN protein from a CS patient with an R189X mutation (Eng, 2003) did not bind to CENP-C. Further experiments showed that the expression of the R189X mutant in wild-type mouse embryo fibroblasts resulted in numerous chromosomal alterations, implying that the mutation can induce massive chromosomal abnormalities in normal cells. Apparently, these results have implications for the development of potential anticancer therapies because many chemotherapeutic agents act through DNA-damage repair mechanisms (reviewed by Planchon et al., 2008) .
Cytoplasmic PTEN has been shown to be proapoptotic (Chung and Eng, 2005) : expression of wildtype or a nuclearlocalization-deficient PTEN showed increased apoptosis (that is, elevated caspase activity) in MCF-7 cells (reviewed by Planchon et al., 2008) . Clearly, the role of nuclear PTEN is different from that of cytoplasmic PTEN. Nuclear PTEN regulates cellular homoeostasis and stability by contributing to chromosome stability, DNA repair and cell cycle arrest. Loss of nuclear PTEN results in chromosomal alterations and unregulated cell cycling. Aside from the PTEN phosphatase activity, the equilibrium between nuclear and cytoplasmic PTEN may also be important in the regulation of apoptosis. Without doubt, future studies will shed more light on the roles of both cytoplasmic and nuclear PTEN in the regulation of carcinogenesis.
PTEN knockout mice: diverse CS phenotypes and genetic background
Information from PTEN studies involving Pten knockout mice can lend us clues in understanding the role of PTEN, its function, its interaction with other genes in the same or related pathways, which may influence the development of CS, although virtually all the murine models do not mimic the human PHTS conditions closely enough to be useful in that manner. Null Pten mutations targeting the phosphatase domain of the protein (Di Cristofano et al., 1998; Suzuki et al., 1998; Podsypanina et al., 1999; Stambolic et al., 2000) have already been generated. Because Pten À/À mice are not viable, mice with a heterozygous knockout (Pten þ /À) are preferred, which spontaneously develop neoplasia, associated with the loss of the normal PTEN allele and an increased activation of AKT, mTOR and P70S6K. As seen in patients with CS, there appears to be vast genotype-phenotype variability among the different mouse models examined so far, none of which truly mirror the human condition (Di Cristofano et al., 1998; Suzuki et al., 1998; Podsypanina et al., 1999; Stambolic et al., 2000) . This strongly suggests that the diverse mutations engineered in each mouse model and/or the genetic backgrounds of the mice used in these studies may act as modifiers, thereby, contributing to the variability of the phenotype observed. Indeed, Freeman et al. (2006) demonstrated that both the onset and the incidence of tumour formation were highly dependent on the genetic background (that is, modifier gene not mutation) of these mice, indicating that modifier genes, not the actual Pten mutation, play a large role in the phenotype presented. These imprecise genotype-phenotype correlations suggest that additional genetic, and almost certainly non-genetic, host and micro/macroenvironmental factors and/or mechanisms contribute to the development, progression and severity of disease in patients with similar mutations.
Future of 'Omics'-ology and PTEN
We have thus far seen, from above, the many layers of complexity that can be encountered while analysing the diverse PHTS phenotypes and the underlying genetic players within the disease pathway. It is important to not only understand these layers but also define them by incorporating data generated across a variety of '-omics' and use sophisticated genetic epidemiology approaches that are able to handle the exponential increment of the interacting multidimensionality of genetic factors (Ritchie et al., 2001; Chanda et al., 2007; Chung et al., 2007; Lee et al., 2007) . It is highly likely that the effect of multiple genes interacting with each other is not often accounted for. With the ever-evolving field of 'interactomics', the interrogation of the network of interactions involving factors that encompass genetic, non-genetic, familial, non-familial, genetic background and environmental factors, will soon be realized in the study of PHTS.
The process of studying phenotypes based on their ancestral genetic backgrounds, phylomics, offers a link between recent common ancestral genetic background, which can also be embedded in diverse haplotypes that are likely to be associated with PHTS. Being able to analyse such ancestral data from both genomic and transcriptomic point of view, using a phylomics approach, will lead to a more biologically informative data. The field of phenomics, transcriptomics, genomics, methylomics, phylomics, interactomics and so on (Harris et al., 2003; Drysdale and Crosby, 2005; Kahraman et al., 2005) has opened avenues and can increase our ability to characterize changes in different cancers through 'multi-omics' analysis. The integration of these multiple approaches will be far more efficient and effective in identifying, refining and validating cancer genes, their participating pathways and biological impact on the cancer phenotypes (Chin et al., 2006; Yao et al., 2006) . In addition, this approach of 'multiomics' analysis will definitely facilitate a multidimensional understanding of the function of PTEN and its interacting partners. Diverse phenotypes at multiple levels can be precisely categorized and statistically modelled to aid in accurate diagnosis and genetic counselling. As we begin to identify additional genes, pathways and molecular markers that can be used to characterize PHTS progression, we should cautiously sieve through meaningful data and be able to correctly interpret enormous output of information that can be used to enhance a more targeted clinical approach (Weber and Eng, 2005a, b) .
